- Advanced search
- Immuno Portal
- Malaria Portal
AlprolixTM is an approved drug (FDA (2014))
Compound class: Peptide or derivative
Comment: AlprolixTM is a recombinant fusion protein combining the peptide for coagulation factor IX with an antibody Fc domain. The presence of the Fc domain increases protein half-life and extends the drug's therapeutic window.
|No information available.
|Summary of Clinical Use
|Designated as an orphan drug by the US FDA, this drug may be used as a prophylactic to reduce bleeding episodes in patients suffering from Hemophilia B. The benefit of this drug is its extended half-life compared to previous treatments, meaning that patients require less frequent injections.
|Mechanism Of Action and Pharmacodynamic Effects
|Replaces the factor IX missing in hemophilia B patients, to restore clotting function and reduce pathological bleeding events.